Compare NUE & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUE | RMD |
|---|---|---|
| Founded | 1905 | 1989 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1B | 32.2B |
| IPO Year | 1994 | N/A |
| Metric | NUE | RMD |
|---|---|---|
| Price | $212.11 | $219.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $183.30 | ★ $293.56 |
| AVG Volume (30 Days) | ★ 1.3M | 852.0K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | 1.05% | ★ 1.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.07 | $10.60 |
| Revenue Next Year | $4.14 | $7.41 |
| P/E Ratio | $28.27 | ★ $25.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $106.21 | $216.68 |
| 52 Week High | $216.26 | $293.81 |
| Indicator | NUE | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 81.94 | 34.90 |
| Support Level | $133.82 | $218.39 |
| Resistance Level | N/A | $260.21 |
| Average True Range (ATR) | 4.69 | 4.80 |
| MACD | 3.54 | 0.11 |
| Stochastic Oscillator | 92.44 | 13.96 |
Nucor Corp manufactures steel and steel products. The company's reportable segments are steel mills, steel products, and raw materials. The majority of its revenue is derived from the steel mills segment, which is engaged in producing sheet steel (hot-rolled, cold-rolled, and galvanized), plate steel, structural steel (wide-flange beams, beam blanks, H-piling, and sheet piling), and bar steel products. Nucor manufactures steel principally from scrap steel and scrap steel substitutes using electric arc furnaces (EAFs), along with continuous casting and automated rolling mills. The steel mills segment sells its products mainly to steel service centers, fabricators, and manufacturers located in the United States, Canada, and Mexico.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.